scholarly journals Esophageal squamous cell cancer in patients with head and neck cancer: Prevalence of human papillomavirus DNA sequences

2003 ◽  
Vol 109 (2) ◽  
pp. 253-258 ◽  
Author(s):  
Ethel-Michele de Villiers ◽  
Karin Gunst ◽  
Harald Stein ◽  
Hans Scherübl
Keyword(s):  
Head And Neck Cancer ◽  
Human Papillomavirus ◽  
Head And Neck ◽  
Neck Cancer ◽  
Squamous Cell ◽  
Dna Sequences ◽  
Squamous Cell Cancer ◽  
Cell Cancer ◽  
Cancer Prevalence ◽  
Papillomavirus Dna

In-human activity and pharmacology of homemade silver nanoparticles in highly refractory metastatic head and neck squamous cell cancer.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e17533-e17533
Author(s):  
Jasmine Singh ◽  
Farjana Fattah ◽  
Tam Burks ◽  
Jie Zheng ◽  
Xingya Jiang ◽  
...  
Keyword(s):  
Silver Nanoparticles ◽  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Squamous Cell ◽  
Squamous Cell Cancer ◽  
Cell Cancer ◽  
The Body ◽  
Complete Regression ◽  
Silver Solution

e17533 Background: Silver nanoparticles (SNPs) show high efficacy as targeted therapy against cancer cell lines, but have never been tested in patient clinical trials. We present the first in-human trial of SNPs in a cancer patient with a dramatic outcome. Methods: Homemade SNP solution is prepared by the patient with online instructions. Current from 3 9-volt batteries is passed across 99.99% pure silver-bar electrodes in distilled water, until the metal content of the water measures 0.09-0.15 parts per million. The manufacturer is a 77-year old male who developed multiple recurrences of nasal cavity squamous cell cancer. Over 2 years he progressed on platinum and taxane based-chemotherapy, radiation twice and 2 surgical resections. Large hepatic and pulmonary metastases were observed on PET, MRI and CT; he was initiated on hospice. Without informing his oncologist he subsequently began manufacturing and consuming the SNP solution. Results: The patient ingested 120 ml daily of the solution for 3 months leading to clinical recovery and complete resolution of cancer at all sites, persisting for 18 months. Electron microscopy of the silver solution revealed bimodal SNP size distributions; 3 & 12 nm. Inductively coupled plasma mass spectrometry showed the basal blood silver ion concentrations of 32 ng/g. One hour after ingesting 60 ml of silver solution it rose to 46 ng/g. Urine showed no SNPs. Toxicities were not noted with this silver solution, with no evidence of myelosuppression, liver or kidney abnormalities on repeated testing. The patient underwent reconstructive surgery with excellent wound healing, and his performance status continues to improve. Conclusions: Ingestion of a SNP solution is associated with complete regression of highly refractory head and neck cancer in the absence of other anticancer therapy. Ingesting silver solution causes a noticeable and nearly immediate rise in blood silver concentration. Urinary excretion is not a major path of clearance from the body. Given these dramatic results that may be attributed to SNP in conjunction with strong preclinical data, further patient testing of SNP should be done to confirm its safety and efficacy in head and neck cancer.

Distant metastases in terminal head and neck cancer patients

1997 ◽  
Vol 111 (5) ◽  
pp. 454-458 ◽  
Author(s):  
Yoav P. Talmi ◽  
Daniel Cotlear ◽  
Alexander Waller ◽  
Zeev Horowitz ◽  
Abraham Adunski ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Cancer Patients ◽  
Neck Cancer ◽  
Squamous Cell ◽  
Squamous Cell Cancer ◽  
Primary Tumour ◽  
Cell Cancer ◽  
Distant Metastases ◽  
Clinical Series

AbstractWith improved control of cancer above the clavicles, distant metastases (DM) are frequently more seen and are becoming a more common cause of morbidity and mortality. The present study defined the incidence of distant metastases in a cohort of terminal head and neck cancer patients (HNCP) and compared it to current reported data. The incidence of distant metastases in relation to the primary tumour was evaluated and their impact on survival was assessed. A retrospective survey of patient charts was made, based on the hospice database and original referring hospital charts. Data of 59 patients admitted to the hospice were evaluated. The incidence and location of locoregional and distant disease were studied and effects on survival analyzed.The overall survival from diagnosis to demise was 42.7 months. Thyroid cancer was seen in 20.3 per cent of cases and squamous cell cancer was seen in 59.3 per cent. Distant metastases were found in 83 per cent and 48.6 per cent of patients respectively. Laryngeal cancer patients had a 54.5 per cent incidence of distant metastases. Locoregional disease was seen in 47 per cent of cases and 35.7 per cent of them had distant metastases while a 64.3 per cent incidence of distant metastases was found in cases without locoregional disease. Mean survival was 47.3 months with distant metastases vs 36.5 months without metastases. The difference was not statistically significant.The incidence of distant metastases in squamous cell cancer in terminalHNCP was 48.6 per cent. This is the highest reported incidence of metastases in a clinical series. Patients without locoregional disease had almost a two-fold incidence of metastases. Survival was not affected by metastases in this series.

Use of Tumor Markers in the Management of Head and Neck Cancer

2000 ◽  
Vol 15 (2) ◽  
pp. 179-183 ◽  
Author(s):  
G. Rosati ◽  
F. Riccardi ◽  
A. Tucci
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Tumor Markers ◽  
Neck Cancer ◽  
Squamous Cell ◽  
Squamous Cell Cancer ◽  
Cell Cancer ◽  
Response To Treatment ◽  
Response To Chemotherapy ◽  
Undifferentiated Tumors

Serologic tumor markers have been evaluated in the diagnosis, management and follow-up of patients with head and neck cancer. However, to the authors’ knowledge no tumor marker has yet been shown to be useful for monitoring the response to chemotherapy in this type of disease, in particular for undifferentiated tumors. The pretreatment levels of CEA, TPA, SCC and ferritin were evaluated in 98 patients with advanced head and neck cancer. Of this group 64 patients were studied sequentially every month during planned chemotherapy and three weeks after treatment using standard commercial kits. The results showed the following sensitivity values: TPA 50%, CEA 36%, SCC 34% and ferritin 19%. The incidence and magnitude of the marker elevations were correlated with the extent of disease. In patients with squamous cell cancer SCC and CEA were elevated (by 68% and 54%, respectively) in tumors with good differentiation (G1), but only by 13% (both markers) in tumors classified as poorly differentiated (G3). CEA, SCC and ferritin serum levels were not correlated with response to chemotherapy, while TPA values correlated with the clinical response to treatment in 100% of patients with undifferentiated cancer and in 75% of those with squamous cell cancer. Our data indicate that in patients with head and neck cancer TPA appears to be a sensitive marker, followed in decreasing order of sensitivity by CEA, SCC and ferritin. However, SCC and CEA seem to be the most suitable markers for squamous cell cancer and in particular for more differentiated tumors (G1). Finally, TPA has proved to be a useful marker for monitoring the response to chemotherapy in patients with head and neck cancer, in particular for undifferentiated tumors.

Genetics of Head and Neck Cancer (Introduction)

1995 ◽  
Vol 112 (5) ◽  
pp. P90-P90
Author(s):  
Michael S. Benninger ◽  
Daniel Vandyke ◽  
Carol Bradford ◽  
Thomas Carey
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Squamous Cell ◽  
Squamous Cell Cancer ◽  
Human Cancer ◽  
Cell Cancer ◽  
Genetic Research ◽  
Educational Objectives ◽  
Human Cancers

Educational objectives: To review basic genetics and cytogenetics as they relate to human cancers and head and neck cancer and to become familiar with the basis of genetics of human cancer and successes in molecular and genetic research of squamous cell cancer.

Results of Combined Radiotherapy and Multidrug Chemotherapy in Advanced Squamous Cell Cancer of the Head and Neck

1986 ◽  
Vol 72 (5) ◽  
pp. 487-490
Author(s):  
Marian Reinfuss ◽  
Stanislaw Korzeniowski
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Squamous Cell ◽  
Squamous Cell Cancer ◽  
Cell Cancer ◽  
Treatment Results ◽  
Free Survival ◽  
Multidrug Chemotherapy ◽  
Radio Chemotherapy ◽  
Higher Doses

Treatment results of combined radiotherapy and polychemotherapy in a group of 38 patients with advanced squamous cell of the head and neck cancer are presented. The radio-chemotherapy schedule included 60Co irradiation with 20 Gy in 10 fractions over two weeks followed by multidrug chemotherapy with vincristin, bleomycin, methotrexate and leucovorin. Three series of radio-chemotherapy were given. In 14 patients the total dose of irradiation was increased to 70-105 Gy. The probabilities of overall and symptom-free survival at 2 years were 32% and 20%, respectively. Treatment results correlated with stage of the disease. Patients who received higher doses of radiation seemed to have better chances of symptom-free survival.

scholarly journals Successful Treatment of Refractory Squamous Cell Cancer of the Head and Neck with Nivolumab and Ipilimumab

2018 ◽  
Vol 11 (1) ◽  
pp. 17-20 ◽  
Author(s):  
Katjana S. Schwab ◽  
Glenn Kristiansen ◽  
Hans H. Schild ◽  
Stefanie E.A. Held ◽  
Annkristin Heine ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Squamous Cell ◽  
Treatment Options ◽  
Cell Cancer ◽  
Metastatic Malignant Melanoma ◽  
Programmed Death ◽  
The Us ◽  
Platinum Refractory

Treatment options for patients with platinum-refractory, recurrent, metastatic head and neck squamous cell carcinoma (HNSCC) are limited, and prognosis is poor. Nivolumab (Opdivo) has been approved by the US Food and Drug Administration (FDA) for the treatment of patients with recurrent or metastatic HNSCC who have disease progression on or after platinum-based therapy. Recently, in patients with metastatic malignant melanoma a significant improvement of outcome and response was achieved with the combination of ipilimumab (CTLA4 antibody) and the programmed death (PD)-1 inhibitor nivolumab compared with monotherapy. Based on these results, the combination of nivolumab and ipilimumab has been approved by the FDA for the treatment of patients with unresectable or metastatic melanoma. So far, there have been no data concerning the combination of nivolumab and ipilimumab in squamous cell head and neck cancer. We here present the case of a 46-year-old male with refractory squamous cell head and neck cancer, who was successfully treated with the PD-1 inhibitor nivolumab in combination with the anti-CTLA4 antibody ipilimumab.

Cetuximab, paclitaxel, carboplatin and radiation for esophageal and gastric cancer

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 4029-4029 ◽  
Author(s):  
M. Suntharalingam ◽  
T. Dipetrillo ◽  
P. Akerman ◽  
H. Wanebo ◽  
B. Daly ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Esophageal Cancer ◽  
Head And Neck Cancer ◽  
Head And Neck ◽  
Squamous Cell ◽  
Squamous Cell Cancer ◽  
Cell Cancer ◽  
Locally Advanced ◽  
Complete Response ◽  
Grade 3

4029 Background: Cetuximab is an IgG1, chimerized, monoclonal antibody that binds specifically to the epidermal growth factor receptor. Cetuximab improves survival when combined with radiation for patients with locally advanced head and neck cancer. We evaluated the safety and efficacy of the addition of cetuximab to concurrent chemoradiation for patients with esophageal and gastric cancer. Methods: Patients with adenocarcinoma or squamous cell cancer of the esophagus or stomach without distant organ metastases were eligible. Patients with locally advanced disease from mediastinal, celiac, portal and gastric lymphadenopathy were eligible. Surgical resection was not required. Clinical complete response was defined as no tumor on postreatment endoscopic biopsy. Patients received cetuximab, 400mg/m2 week #1 then 250 mg/m2/week for 5 weeks, paclitaxel, 50 mg/m2/week, and carboplatin, AUC =2 weekly for 6 weeks, with concurrent 50.4 Gy radiation. Results: Thirty-seven patients have been entered. The median age was 61 (range of 30–87). Thirty-four have esophageal cancer and 3 have gastric cancer. Of the patients with esophageal cancer, twenty-five have adenocarcinoma and nine have squamous cell cancer. Thus far, 30 patients have completed treatment and are evaluable for toxicity. There have been no grade 4 non-hematologic toxicities and 1 pt had grade 4 neutropenia (3%). Six patients (20%) had grade 3 esophagitis. Other grade 3 toxicities included dehydration (n=5), rash (n=9), and paclitaxel/cetuximab hypersensitivity reactions (n=2). Eighteen of 27 patients (67%) have had clinical complete response. Seven pts out of 16 (43%) who have gone to surgery have had a pathologic CR. Conclusions: Cetuximab can be safely administered with chemoradiation for patients with esophageal cancer. Consistent with the data in head and neck cancer, cetuximab increases cutaneous toxicity but does not increase mucositis/esophagitis when combined with chemoradiation. Further evaluation is ongoing. [Table: see text]

Sign in / Sign up

Export Citation Format

Share Document